Compare Ionis Pharmaceuticals Inc. Common Stock (IONS) vs Marex Group Limited Ordinary Shares (MRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ionis Pharmaceuticals Inc. Common Stock vs Marex Group Limited Ordinary Shares — how do they compare? Ionis Pharmaceuticals Inc. Common Stock trades at $43 (market cap $7.04B), while Marex Group Limited Ordinary Shares trades at $68.92 (market cap $5.18B). The key difference: Ionis Pharmaceuticals Inc. Common Stock is the larger of the two by market cap, and Marex Group Limited Ordinary Shares pays a 0.89% dividend while Ionis Pharmaceuticals Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ionis Pharmaceuticals Inc. Common Stock for 0 Days and Marex Group Limited Ordinary Shares for 3 Days on average.
| IONS | MRX | |
|---|---|---|
Market Cap | $7.04B | $5.18B |
Volume | 2,977,440 | 794,309 |
Sector | Health | Financials |
52-Week High | $86.50 | $78.27 |
52-Week Low | $42.38 | $29.92 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $6.60B | $8.26B |
Dividend Yield | — | 0.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MRX trades at $71.95, down 0.47% on the day, with a neutral technical signal despite bullish moving averages. The company demonstrates strong fundamentals with a P/E of 14.62 and robust profitability, including a 9.69% net income margin and 27.57% ROE. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $1.64 surpassing the $1.36 estimate. Positive news includes record H1 2026 results and strategic developments in financial infrastructure.
The outlook for MRX is positive, supported by strong earnings momentum, a 100% buy rating from analysts, and a consensus price target of $83.67 implying significant upside. Key risks include execution of its acquisition strategy and market volatility. The stock's current valuation and growth trajectory present a compelling opportunity, though investors should monitor debt levels and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ionis Pharmaceuticals Inc. Common Stock
Ionis Pharmaceuticals Inc. is a biopharmaceutical company that develops RNA-targeted medicines using its antisense technology, with marketed treatments in neurology and cardiometabolic disease.
Read more on IONS →About Marex Group Limited Ordinary Shares
Marex Group provides financial services across commodities, financial markets, and corporate clients. Its services include clearing, agency and execution, market making, hedging, and securities services.
Read more on MRX →
